VRSN
53
-4
DVN
21
3
HSIC
56
5
UPS
60
9
WBA
48
4
SIG
52
3
LRCX
43
-2
CSCO
67
4
STZ
54
-3
XRAY
28
2
MSFT
50
3
UA
50
-9
BAC
53
3
EOG
58
2
URI
65
5
IBM
58
-2
NVDA
56
-4
EFX
38
2
NRG
49
-3
PG
56
5
VRSN
53
-4
DVN
21
3
HSIC
56
5
UPS
60
9
WBA
48
4
SIG
52
3
LRCX
43
-2
CSCO
67
4
STZ
54
-3
XRAY
28
2
MSFT
50
3
UA
50
-9
BAC
53
3
EOG
58
2
URI
65
5
IBM
58
-2
NVDA
56
-4
EFX
38
2
NRG
49
-3
PG
56
5
Financhill
Back

CytomX Therapeutics 10K Form

Sell
28

CTMX
CytomX Therapeutics

Last Price:
0.89
Seasonality Move:
13.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CTMX News And Ratings

See the #1 stock for the next 7 days that we like better than CTMX

CTMX Financial Statistics

Sales & Book Value

Annual Sales: $101.21M
Cash Flow: $-20.75M
Price / Cash Flow: 0
Annual Sales: $-0.30
Price / Book: 0

Profitability

EPS (TTM): 0.17000
Net Income (TTM): $13.83M
Gross Margin: $890K
Return on Equity: 0%
Return on Assets: 7.63%

CytomX Therapeutics Earnings Forecast

Key CytomX Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 1 years for CTMX is 100.00%.
  • The Selling, General & Administrative Expenses for CTMX have been equal to 29.66% of Gross Profit Margin.
  • The Research & Development expenses have been 76.75% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CTMX is -0.56% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

CytomX Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CTMX
CUSIP: 23284F
Website: cytomx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.04
Quick Ratio: 1.01

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CTMX Technical Analysis vs Fundamental Analysis

Sell
28
CytomX Therapeutics (CTMX) is a Sell

Is CytomX Therapeutics a Buy or a Sell?